Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    Development of a serological assay SERO to identify SARS-CoV-2 antibodies SERO in COVID-19 patients

    Authors: Angela Huynh; Donald M Arnold; John G Kelton; James W Smith; Jane C Moore; Vasudhevan T Chetty; Hannah D Stacey; Jann C Ang; Zain Chagla; Bart J Harvey; Dawn ME Bowdish; Matthew S Miller; Ishac Nazy; Anna Smed Sorensen; Jonas Klingstrom; Andreas Brave

    doi:10.1101/2020.09.11.20192690 Date: 2020-09-13 Source: medRxiv

    Coronavirus Disease MESHD 2019 (COVID-19) is a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). While molecular assays are used to detect viral genetic material for the diagnosis of acute infection MESHD, reliable serological assays SERO are needed to measure immunity against SARS-CoV-2. In this report, we describe an enzyme-linked immunosorbent assay SERO ( ELISA SERO) that detects antibodies SERO against the following SARS-CoV-2 recombinant proteins: the full-length spike (S) protein and the receptor-binding domain (RBD). Our assay is sensitive and specific for immunoglobulin (Ig) G, IgA and IgM anti-S protein and anti-RBD antibodies SERO. Samples were pre-treated with Triton X-100 to inactivate potential virus without affecting antibody SERO detection. Our in-house ELISA SERO performed as well as the commercial EUROIMMUN and Ortho assays for anti- SARS-CoV-2 antibodies SERO. This method provides a high-throughput assay that does not require specialized instrumentation and can be widely used to determine immunity and the dynamic range of antibodies SERO found within SARS-CoV-2.

    Effect of novel coronavirus disease MESHD 2019 infection on chronic HP infection on chronic MESHD kidney disease G1-G5, G5 Dialysis and G5 Transplantation

    Authors: Fateme Shamekhi Amiri

    doi:10.21203/rs.3.rs-66274/v1 Date: 2020-08-26 Source: ResearchSquare

    Background: The pneumonia HP pneumonia MESHD caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease MESHD that causes lethal disease and multiorgan failure MESHD. The aim of this research is to investigate association between covid-19 infection MESHD and kidney dysfunction MESHD.Methods and materials: In this retrospective study, sixty-eight patients with kidney dysfunction MESHD and covid-19 infection MESHD were investigated. Clinical features, laboratory data at initial presentation, management and outcomes were collected.The paper has written based on searching PubMed Central and Google Scholar to identify potentially relevant articles. Median, percentage, mean ± standard deviation (SD), two-tailed t and chi-square and Cohen᾽s-d tests were used for statistical analyses. Moreover, relative risk, odds ratio, pearson᾽s correlation for statistical analyses were used. Results: The average age TRANS of patients at time of diagnosis in covid-19 nephropathy HP nephropathy MESHD was 52.04 ± 14.42 years (ranging from 24 years to 88 years). There was not statistical significance correlation between lymphocytopenia MESHD and serum SERO creatinine (SCr) in covid-19 nephropathy HP nephropathy MESHD (R2=0.063; p-value= 0.33).  Effect size of elevated IL-6 on decreased estimated glomerular filtration rate (eGFR) in covid-19 nephropathy HP nephropathy MESHD was assessed 0.656 (medium effect size). Relative risk and odds ratio of acute kidney disease MESHD ( AKD MESHD) in covid-19 nephropathy HP nephropathy MESHD were assessed 0.57 and 0.4, respectively (p-value: 0.422). Correlation between SCr changes and time of emergent AKI MESHD ( acute kidney injury HP acute kidney injury MESHD), AKD MESHD and chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD) was assessed with R2 of 0.0003 and p-value of 0.94 (not significant).  Conclusion: The present study revealed medium effect size of elevated IL-6 on decreased eGFR. Future clinical research is required for investigating novel unknown findings in covid-19 nephropathy HP nephropathy MESHD

    Acute gastrointestinal injury MESHD in critically ill MESHD patients with coronavirus disease MESHD 2019 in Wuhan, China

    Authors: Jia-Kui Sun

    doi:10.1101/2020.03.25.20043570 Date: 2020-03-27 Source: medRxiv

    Background: To investigate the prevalence SERO and outcomes of acute gastrointestinal injury MESHD ( AGI MESHD) in critically ill MESHD patients with coronavirus disease MESHD 2019 (COVID-19). Methods: In this clinical retrospective study, demographic data, laboratory parameters, AGI MESHD grades, clinical severity and outcomes were collected. The primary endpoints were AGI MESHD incidence and 28-day mortality, the secondary endpoints were organ dysfunction MESHD and septic shock MESHD shock HP incidence. Results: From February 10 to March 10 2020, 83 critically ill patients of 1314 patients with COVID-19 were enrolled. Seventy-two (86.7%) patients had AGI MESHD during hospital stay, of them, 30 had AGI MESHD grade I, 35 had AGI MESHD grade II, 5 had AGI MESHD grade III, and 2 had AGI MESHD grade IV. The incidence of AGI MESHD grade II and above was 50.6%. As of March 16, 40 (48.2%) patients died within 28 days of admission, the median hospital stay was 12.0 days, ranging from 3 days to 27 days. Multiple organ dysfunction syndrome MESHD developed in 58 (69.9%) patients, septic shock MESHD shock HP in 16 (19.3%) patients. Patients with worse AGI MESHD grades had worse clinical variables, higher septic shock MESHD shock HP incidence and 28-day mortality. Sequential organ failure assessment scores (SOFA) (95% CI, 1.374-2.860; P <0.001), white blood SERO cell (WBC) counts (95% CI, 1.037-1.379; P =0.014), duration of mechanical ventilation (MV) (95% CI, 1.020-1.340; P =0.025) were risk factors for the development of AGI MESHD grade II and above. Non-survivors were accompanied by higher incidence of AGI MESHD grade III to IV than survivors (17.5% vs. 0.0%, P =0.004). Conclusions: The AGI MESHD incidence was 86.7%, and hospital mortality was 48.2% in critically ill patients with COVID-19. SOFA scores, WBC counts, and duration of MV were risk factors for the development of AGI MESHD grade II and above. Patients with worse AGI MESHD grades had worse clinical severity variables, higher septic shock MESHD shock HP incidence and 28-day mortality.

    A serological assay SERO to detect SARS-CoV-2 seroconversion in humans

    Authors: Fatima Amanat; Daniel Stadlbauer; Shirin Strohmeier; Thi Nguyen; Veronika Chromikova; Meagan McMahon; Kaijun Jiang; Guha Asthagiri-Arunkumar; Denise Jurczyszak; Jose Polanco; Maria Bermudez-Gonzalez; Giulio Kleiner; Teresa Aydillo; Lisa Miorin; Daniel Fierer; Luz Amarilis Lugo; Erna Milunka Kojic; Jonathan Stoever; Sean T.H. Liu; Charlotte Cunningham-Rundles; Philip L. Felgner; Daniel Caplivski; Adolfo Garcia-Sastre; Allen Cheng; Katherine Kedzierska; Olli Vapalahti; Jussi Hepojoki; Viviana Simon; Florian Krammer; Thomas Moran

    doi:10.1101/2020.03.17.20037713 Date: 2020-03-18 Source: medRxiv

    SARS-Cov-2 (severe acute respiratory disease MESHD coronavirus 2), which causes Coronavirus Disease MESHD 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection MESHD, we currently lack serological assays SERO suitable to specifically detect SARS-CoV-2 antibodies SERO. Here we describe serological enzyme-linked immunosorbent assays SERO ( ELISA SERO) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples representing pre-COVID 19 background immunity in the general adult TRANS population as well as samples from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma SERO/ serum SERO as early as two days post COVID19 symptoms onset TRANS. Importantly, these assays do not require handling of infectious virus, can be adjusted to detect different antibody SERO types and are amendable to scaling. Such serological assays SERO are of critical importance to determine seroprevalence SERO in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum SERO as therapeutic. Sensitive and specific identification of coronavirus SARS-Cov-2 antibody SERO titers may, in the future, also support screening of health care workers to identify those who are already immune and can be deployed to care for infected MESHD patients minimizing the risk of viral spread to colleagues and other patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.